Showing 20 of 203 recruiting trials for “combined-hepatocellular-carcinoma-and-cholangiocarcinoma”
Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
T-Cell Therapy (ECT204) in Adults With Advanced HCC
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
👨⚕️ Jonathan M Hernandez, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Mar 2022View details ↗
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer
👨⚕️ Julien Edeline, MD, Centre de Lutte contre le Cancer Eugène Marquis📍 7 sites📅 Started Feb 2022View details ↗
GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma
RecruitingNCT05187312 ↗
Registry for Advanced Endoscopy
A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
RecruitingNCT04792801 ↗
PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC
RecruitingNCT05714124 ↗
Liver Embolization Approaches for Tumor Management
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
👨⚕️ Andrea Cercek, MD, Memorial Sloan Kettering Cancer Center📍 11 sites📅 Started May 2021View details ↗
Artificial Intelligence vs. LIRADS in Diagnosing HCC on CT
RecruitingNCT04946773 ↗
Deep Liver Phenotyping and Immunology Study
RecruitingNCT04753996 ↗
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
👨⚕️ Zhenfeng Zhang, MD, PhD, Second Affiliated Hospital of Guangzhou Medical University📍 1 site📅 Started Jan 2021View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →